NCT06702826View on ClinicalTrials.gov

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Non Small Cell Lung CancerBrain MetastasesStereotactic RadiationImmunotherapy
Interventions
DRUG

Cadonilimab combined with SRS

Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone

Trial Locations (1)

Unknown

RECRUITING

Xiangya Hospital, Central South University, Changsha

All Listed Sponsors
lead

Rongrong Zhou

OTHER